SOLID TUMOR DNA PROFILER NEXT

This test uses Next Generation Sequencing (NGS) technology to analyze the DNA of a solid tumor for a wide range of genetic mutations, alterations, and biomarkers. It helps in identifying the molecular characteristics of the tumor, which can guide treatment decisions, predict prognosis, and even determine eligibility for targeted therapies or clinical trials.

Every tumor is genetically unique, even among the same cancer types. The Solid Tumor DNA Profiler allows clinicians to understand the tumor's genetic drivers, offering a more personalized treatment approach. It plays a crucial role in precision oncology, especially in cases where standard therapies have failed or when advanced cancer requires a more strategic intervention.

This test is generally recommended for patients with advanced, recurrent, or metastatic cancers. It is also used when there is a need for targeted therapy or immunotherapy and helps guide decisions around second-line or experimental treatments based on specific mutations.

The test provides a comprehensive report detailing any gene mutations, fusions, amplifications, or deletions present in the tumor. Based on these findings, oncologists can match the genetic alterations to FDA-approved treatments or ongoing clinical trials, significantly improving treatment outcomes.

A tumor tissue sample obtained through biopsy or surgery is processed for DNA extraction. Using NGS, hundreds of genes are sequenced in parallel to generate a detailed genomic profile of the tumor. Results are typically available within a few weeks.